Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase Cβ inhibition and renin-angiotensin system blockade: A pilot study

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 1, 2012, Pages 113-121

  Cherney, David Z I ^a   Reich, Heather N ^a   Scholey, James W ^a   Lai, Vesta ^a   Slorach, Cameron ^b   Zinman, Bernard ^c   Bradley, Timothy J ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Angiotensin ii; Endothelial function; Hyperglycemia; Inhibition; Protein kinase C ; Type 1 diabetes mellitus

Indexed keywords

ANGIOTENSIN II; PLACEBO; PROTEIN KINASE C BETA; RUBOXISTAURIN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION;

ADULT; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; ENZYME INHIBITORS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEMODYNAMICS; HUMANS; HYPERGLYCEMIA; INDOLES; INFUSIONS, INTRAVENOUS; MALE; MALEIMIDES; PILOT PROJECTS; PROTEIN KINASE C; RENIN-ANGIOTENSIN SYSTEM;

EID: 84855616465     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y11-106     Document Type: Article

References (39)

1. Beckman, J.A., Goldfine, A.B., Gordon, M.B., Garrett, L.A., and Creager, M.A. 2002. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ. Res. 90(1): 107-111. doi:10.1161/hh0102.102359.
2. Beckman, J.A., Goldfine, A.B., Goldin, A., Prsic, A., Kim, S., and Creager, M.A. 2010. Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetes. J. Clin. Endocrinol. Metab. 95(8): 3783-3787. doi:10.1210/jc.2010-0286.
3. Boesch, D.M., and Garvin, J.L. 2001. Age-dependent activation of PKC isoforms by angiotensin II in the proximal nephron. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281(3): R861-R867.
4. Brooks, B., Delaney-Robinson, C., Molyneaux, L., and Yue, D.K. 2008. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin. J. Diabetes Complications, 22(2): 88-95. doi:10.1016/j.jdiacomp.2007.07.002.
5. Brown, M.J. 2008. Aliskiren. Circulation, 118(7): 773-784. doi:10.1161/CIRCULATIONAHA.108.787630.
6. Cattan, V., Kakou, A., Louis, H., and Lacolley, P. 2006. Pathophysiology, genetic, and therapy of arterial stiffness. Biomed. Mater. Eng. 16(4 Suppl.): S155-S161.
7. Cherney, D.Z., Miller, J.A., Scholey, J.W., Bradley, T.J., Slorach, C., Curtis, J.R., et al. 2008a. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes, 57(3): 688-695. doi:10.2337/db07-1230.
8. Cherney, D.Z., Scholey, J.W., Nasrallah, R., Dekker, M.G., Slorach, C., Bradley, T.J., et al. 2008b. Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. Am. J. Physiol. Renal Physiol. 294(6): F1336-F1341. doi:10.1152/ajprenal.00574.2007.
9. Cherney, D.Z., Konvalinka, A., Zinman, B., Diamandis, E.P., Soosaipillai, A., Reich, H., et al. 2009. Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care, 32(1): 91-93. doi:10.2337/dc08-1609.
10. Cherney, D.Z., Lai, V., Scholey, J.W., Miller, J.A., Zinman, B., and Reich, H.N. 2010a. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care, 33(2): 361-365. doi:10.2337/dc09-1303.
11. Cherney, D.Z., Miller, J.A., Scholey, J.W., Nasrallah, R., Hebert, R.L., Dekker, M.G., et al. 2010b. Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes. Diabetes Care, 33(6): 1344-1346. doi:10.2337/dc09-2340.
12. Donaghue, K.C., Robinson, J., McCredie, R., Fung, A., Silink, M., and Celermajer, D.S. 1997. Large vessel dysfunction in diabetic adolescents and its relationship to small vessel complications. J. Pediatr. Endocrinol. Metab. 10(6): 593-598.
13. Ficociello, L.H., Perkins, B.A., Silva, K.H., Finkelstein, D.M., Ignatowska-Switalska, H., Gaciong, Z., et al. 2007. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensinconverting enzyme inhibitors. Clin. J. Am. Soc. Nephrol. 2(3): 461-469. doi:10.2215/CJN.03691106.
14. Franklin, S.S., Khan, S.A., Wong, N.D., Larson, M.G., and Levy, D. 1999. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation, 100(4): 354-360.
15. Gilbert, R.E., Kim, S.A., Tuttle, K.R., Bakris, G.L., Toto, R.D., McGill, J.B., et al. 2007. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care, 30(4): 995-996. doi:10. 2337/dc06-2079.
16. Gokce, N., Keaney, J.F., Jr, Hunter, L.M., Watkins, M.T., Nedeljkovic, Z.S., Menzoian, J.O., and Vita, J.A. 2003. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J. Am. Coll. Cardiol. 41(10): 1769-1775. doi:10.1016/S0735-1097(03)00333-4.
17. Gordin, D., Ronnback, M., Forsblom, C., Heikkila, O., Saraheimo, M., and Groop, P.H. 2007. Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes. Diabetologia, 50(9): 1808-1814. doi:10.1007/s00125-007-0730-0.
18. Hashimoto, M., Akishita, M., Eto, M., Ishikawa, M., Kozaki, K., Toba, K., et al. 1995. Modulation of endothelium-dependent flowmediated dilatation of the brachial artery by sex and menstrual cycle. Circulation, 92(12): 3431-3435.
19. Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., et al. 2001. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88(2): E14-E22.
20. Ishii, H., Jirousek, M.R., Koya, D., Takagi, C., Xia, P., Clermont, A., et al. 1996. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science, 272(5262): 728-731. doi:10.1126/science.272.5262.728.
21. Ishii, H., Koya, D., and King, G.L. 1998. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J. Mol. Med. 76(1): 21-31. doi:10.1007/s109-1998-8101-y.
22. Jirousek, M.R., Gillig, J.R., Gonzalez, C.M., Heath, W.F., McDonald, J.H., 3rd, Neel, D.A., et al. 1996. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cb. J. Med. Chem. 39(14): 2664-2671. doi:10.1021/jm950588y.
23. Kang, N., Alexander, G., Park, J.K., Maasch, C., Buchwalow, I., Luft, F.C., and Haller, H. 1999. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int. 56 (5): 1737-1750. doi:10.1046/j.1523-1755.1999.00725.x.
24. Kawano, H., Motoyama, T., Hirashima, O., Hirai, N., Miyao, Y., Sakamoto, T., et al. 1999. Hyperglycemia rapidly suppresses flowmediated endothelium-dependent vasodilation of brachial artery. J. Am. Coll. Cardiol. 34(1): 146-154. doi:10.1016/S0735-1097(99)00168-0.
25. Mann, J.F., Schmieder, R.E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., et al. ONTARGET investigators. 2008. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet, 372(9638): 547-553. doi:10. 1016/S0140-6736(08)61236-2.
26. Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., et al. 2009. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361(1): 40-51. doi:10.1056/NEJMoa0808400.
27. Mehta, N.N., Sheetz, M., Price, K., Comiskey, L., Amrutia, S., Iqbal, N., et al. 2009. Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovasc. Drugs Ther. 23(1): 17-24. doi:10.1007/s10557-008-6144-5.
28. Miller, J.A. 1999. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J. Am. Soc. Nephrol. 10(8): 1778-1785.
29. Miller, J.A., Floras, J.S., Zinman, B., Skorecki, K.L., and Logan, A.G. 1996. Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin. Sci. (Lond.), 90(3): 189-195.
30. Miller, J.A., Cherney, D.Z., Duncan, J.A., Lai, V., Burns, K.D., Kennedy, C.R., et al. 2006. Gender differences in the renal response to renin-angiotensin system blockade. J. Am. Soc. Nephrol. 17(9): 2554-2560. doi:10.1681/ASN.2005101095.
31. Nagahama, T., Hayashi, K., Ozawa, Y., Takenaka, T., and Saruta, T. 2000. Role of protein kinase C in angiotensin II-induced constriction of renal microvessels. Kidney Int. 57(1): 215-223. doi:10.1046/j.1523-1755.2000.00822.x.
32. Smith, A., Karalliedde, J., De Angelis, L., Goldsmith, D., and Viberti, G. 2005. Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes. J. Am. Soc. Nephrol. 16(4): 1069-1075. doi:10.1681/ASN.2004090769.
33. Sochett, E.B., Cherney, D.Z., Curtis, J.R., Dekker, M.G., Scholey, J.W., and Miller, J.A. 2006. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J. Am. Soc. Nephrol. 17(6): 1703-1709. doi:10.1681/ASN.2005080872.
34. Stehouwer, C.D., Gall, M.A., Twisk, J.W., Knudsen, E., Emeis, J.J., and Parving, H.H. 2002. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes, 51(4): 1157-1165. doi:10.2337/diabetes.51.4.1157.
35. Tesfamariam, B., Brown, M.L., and Cohen, R.A. 1991. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest. 87(5): 1643-1648. doi:10.1172/JCI115179.
36. Tuttle, K.R. 2008. Protein kinase C-beta inhibition for diabetic kidney disease. Diabetes Res. Clin. Pract. 82(Suppl 1): S70-S74. doi:10.1016/j.diabres.2008.09.041.
37. Tuttle, K.R., Bakris, G.L., Toto, R.D., McGill, J.B., Hu, K., and Anderson, P.W. 2005. The effect of ruboxista urin on nephropathy in type 2 diabetes. Diabetes Care, 28(11): 2686-2690. doi:10.2337/diacare.28.11.2686.
38. Weiss, R.H., and Ramirez, A. 1998. TGF-beta - and angiotensin-IIinduced mesangial matrix protein secretion is mediated by protein kinase C. Nephrol. Dial. Transplant. 13(11): 2804-2813. doi:10.1093/ndt/13.11.2804.
39. Wilkinson, I.B., MacCallum, H., Rooijmans, D.F., Murray, G.D., Cockcroft, J.R., McKnight, J.A., and Webb, D.J. 2000. Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM, 93(7): 441-448. doi:10.1093/qjmed/93.7.441.